Duvortuxizumab

From WikiMD's Wellnesspedia

Duvortuxizumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Janssen Pharmaceutica.

Mechanism of Action[edit | edit source]

Duvortuxizumab is a monoclonal antibody that targets the CD19 antigen, a protein expressed on the surface of B-cell lymphomas and leukemias. By binding to this antigen, duvortuxizumab can direct the body's immune system to destroy the cancer cells.

Clinical Trials[edit | edit source]

Duvortuxizumab has been tested in clinical trials for the treatment of Non-Hodgkin lymphoma and Acute lymphoblastic leukemia. The results of these trials have shown promise, but further research is needed to determine the drug's efficacy and safety profile.

Side Effects[edit | edit source]

Like all drugs, duvortuxizumab can cause side effects. The most common side effects reported in clinical trials include fever, fatigue, and nausea. More serious side effects can include infection, anemia, and neutropenia.

See Also[edit | edit source]

References[edit | edit source]


Duvortuxizumab Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD